Welcome to our dedicated page for VivoSim Labs SEC filings (Ticker: VIVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The VivoSim Labs, Inc. (VIVS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq‑listed pharmaceutical and biotechnology services company, VivoSim Labs uses these filings to report on corporate governance, executive compensation, auditor ratification, board elections and other matters relevant to stockholders.
Core documents include annual proxy statements on Schedule 14A, where the company outlines items such as the election of directors, the ratification of its independent registered public accounting firm, advisory votes on executive compensation and the frequency of say‑on‑pay votes. These materials also summarize aspects of VivoSim Labs’ governance framework, including board composition, independence, committee structure and compensation practices.
Current reports on Form 8‑K provide timely disclosure of specific events, such as the appointment of key executives. For example, VivoSim Labs has filed an 8‑K describing the appointment of a Chief Commercial Officer, including information about the role, background and related compensatory arrangements. Another 8‑K reports the results of the company’s annual meeting of stockholders, detailing vote counts for director elections, auditor ratification and advisory proposals.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the significance of each document in clear language. Users can quickly understand the outcomes of stockholder votes, changes in leadership roles and the structure of executive compensation without reading every page of the underlying filing. The page also surfaces Forms 10‑K and 10‑Q when available, along with Forms 4 and other ownership reports, enabling investors to review periodic reporting and insider transaction disclosures with AI‑generated highlights and context.
VivoSim Labs filed its definitive proxy for the 2025 Annual Meeting, to be held virtually on December 16, 2025 at 9:00 a.m. Pacific. Stockholders can attend, ask questions, and vote via webcast at www.virtualshareholdermeeting.com/VIVS2025.
Four items are up for vote: elect two Class II directors (Douglas Jay Cohen and David Gobel) to terms expiring in 2028; ratify Rosenberg Rich Baker Berman P.A. as independent auditor for the fiscal year ending March 31, 2026; approve, on an advisory basis, named executive officer compensation; and approve, on an advisory basis, holding the say‑on‑pay vote every one year. The Board recommends FOR all proposals and “ONE YEAR” on frequency.
The record date is October 17, 2025, with 2,607,962 shares of common stock outstanding. A quorum requires the presence, in person or by proxy, of 869,321 shares, representing one‑third of shares entitled to vote. Fiscal 2025 audit fees billed by RRBB P.A. totaled $260,000.
VivoSim Labs, Inc. filed an S-8 registration statement to register securities under its employee benefit plan. The filing notes a 1-for-12 reverse stock split effected March 20, 2025, and incorporates by reference the company’s recent Annual Report (fiscal year ended March 31, 2025) and certain subsequent Current Reports and Quarterly Report. The exhibit list includes amended charters and bylaws, the Amended and Restated 2022 Equity Incentive Plan and award agreement forms, legal opinion and auditor consent. The filing is signed by senior officers on August 28, 2025.
VivoSim Labs, Inc. reported an equity award to its Chief Commercial Officer, Lialin Tony Serge. The filing shows an option to purchase 40,000 shares of common stock with an exercise price of $1.78 each, exercisable beginning 08/11/2025 and expiring 08/11/2035. The option vests over four years with 25% vesting on 08/11/2026 and the remainder vesting in 12 equal quarterly installments thereafter. Following the grant the reporting person beneficially owns 40,000 options on a direct basis.
VivoSim Labs, Inc. (VIVS) filed an initial Form 3 reporting that Tony Serge Lialin (address on file) is identified as an officer with the title Chief Commercial Officer. The filing, dated for the event on 08/11/2025, states explicitly that no securities are beneficially owned by the reporting person at the time of this statement. The form was submitted by a single reporting person and includes an exhibit referencing a power of attorney.
VivoSim Labs, Inc. appointed Tony Lialin as Chief Commercial Officer effective August 11, 2025. Mr. Lialin brings more than two decades of commercial experience in life sciences and will lead the company’s go-to-market strategy, partnerships, and expansion of San Diego services that combine organ-specific 3D models with AI-driven analytics. His initial annualized salary is $360,000 with a $10,000 sign-on bonus and eligibility for a performance bonus with a target up to 40% of base salary. The company granted a 40,000-share option under its 2022 Equity Incentive Plan vesting over four years (25% after one year, then quarterly thereafter). The Offer Letter and a press release are filed as Exhibits 10.1 and 99.1, respectively. Employment is at-will and no related-party or family relationships were reported.
VivoSim Labs reports a quarter of continued transition from clinical-stage drug development to a services and preclinical discovery business. Revenue was minimal at $37,000 from royalties while product revenue ceased following the winding down of Mosaic. The company recorded a $2.843 million net loss for the three months ended June 30, 2025 and cash and cash equivalents declined to $9.1 million, with total assets of $11.98 million and working capital of about $7.6 million.
In March 2025 VivoSim sold its FXR program for $10.0 million ($9.0M at closing, $1.0M in escrow and up to $50.0M in milestone payments). Management disclosed substantial doubt about going concern for the next year and expects to require additional financing; it reported net cash used in operations of $3.94 million in the quarter. The company highlights scientific progress: its liver NAM platform showed 87.5% sensitivity and 100% specificity on a test set presented in May 2025. Management forecasts fiscal 2026 operating expenses of $10–11 million and continues to sell shares through its ATM program.